Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant staphylococcus aureus nosocomial pneumonia in Germany

Infection

Volumn 37, Issue 2, 2009, Pages 123-132

  De Cock, E ^a   Krueger, W A ^b,c   Sorensen, S ^d   Baker, T ^d   Hardewig, J ^e   Duttagupta, S ^e   Muller E ^f,g   Piecyk, A ^h   Reisinger, E ⁱ   Resch, A ^j  

^a United BioSource Corporation   (Spain)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c KLINIKUM KONSTANZ   (Germany)

^d UNITED BIOSOURCE CORPORATION   (United States)

^e PFIZER INC   (United States)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g Thoraxzentrum Ruhrgebiet   (Germany)

^h Stadtspital Triemli Departement fur Innere Medizin Abteilung fur Gastroenterologie   (Switzerland)

ⁱ ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^j Universitätsklinikum Rostock ^*  (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CEFEPIME; CILASTATIN; IMIPENEM; LINEZOLID; RIFAMPICIN; VANCOMYCIN;

AGED; ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; GERMANY; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL INFECTION; HUMAN; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ACETAMIDES; COST-BENEFIT ANALYSIS; CROSS INFECTION; DECISION SUPPORT TECHNIQUES; DRUG COSTS; FEMALE; GERMANY; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MODELS, ECONOMIC; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; RETROSPECTIVE STUDIES; VANCOMYCIN;

EID: 67349284086     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-8046-7     Document Type: Article

References (40)

1. M.J. Richards J.R. Edwards D.H. Culver R.P. Gaynes 2000 Nosocomial infections in combined medical-surgical intensive care units in the United States Infect Control Hosp Epidemiol 21 510 515 (Pubitemid 30647154)
2. J.L. Vincent D.J. Bihari P.M. Suter H.A. Bruining J. White M.H. Nicolas-Chanoin M. Wolff R.C. Spencer M. Hemmer 1995 The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 274 639 644
3. P. Gastmeier D. Sohr C. Geffers I. Zuschneid M. Behnke H. Ruden 2005 Mortality in German intensive care units: dying from or with a nosocomial infection? Anasthesiol Intensivmed Notfallmed Schmerzther 40 267 272 (Pubitemid 40769840)
4. P. Gastmeier D. Sohr C. Geffers M. Behnke F. Daschner H. Ruden 2005 Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German Nosocomial Infection Surveillance System (KISS) Infection 33 50 55 (Pubitemid 40590991)
5. P. Gastmeier C. Geffers D. Sohr F. Schwab M. Behnke H. Ruden 2003 Surveillance of nosocomial infections in intensive care units. Current data and interpretations Wien Klin Wochenschr 115 99 103 (Pubitemid 36285814)
6. D.J. Diekema M.A. Pfaller F.J. Schmitz J. Smayevsky J. Bell R.N. Jones M. Beach 2001 Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 32 s114 s132 (Pubitemid 32424266)
7. European Antimicrobial Resistance Surveillance System 2005 National Institute of Public Health and the Environment RIVM, Department of Infectious Disease Epidemiology Bilthoven, The Netherlands European Antimicrobial Resistance Surveillance System (EARSS) Database: National Institute of Public Health and the Environment. RIVM, Department of Infectious Disease Epidemiology, Bilthoven, The Netherlands; 2005. Available at http://www.earss.rivm.nl/PAGINA/ interwebsite/database.html
8. T.G. Gleason T.D. Crabtree S.J. Pelletier D.P. Raymond T.B. Karchmer T.L. Pruett R.G. Sawyer 1999 Prediction of poorer prognosis by infection with antibiotic-resistant gram-positive cocci than by infection with antibiotic-sensitive strains Arch Surg 134 1033 1040 (Pubitemid 29473187)
9. S.E. Cosgrove G. Sakoulas E.N. Perencevich M.J. Schwaber A.W. Karchmer Y. Carmeli 2003 Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 53 59 (Pubitemid 36099097)
10. S.E. Cosgrove Y. Qi K.S. Kaye S. Harbarth A.W. Karchmer Y. Carmeli 2005 The impact of methicillin resistance in Staphylococcus bacteremia on patient outcomes: mortality, length of stay, and hospital charges Infect Control Hosp Epidemiol 26 166 174 (Pubitemid 40445022)
11. A.F. Shorr A. Combes M.H. Kollef J. Chastre 2006 Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy Crit Care Med 34 700 706 (Pubitemid 43308259)
12. American Thoracic Society Infectious Diseases Society of America 2005 Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 15 388 416 (Pubitemid 40227463)
13. D.L. Stevens 2006 The role of vancomycin in the treatment paradigm Clin Infect Dis 42 S51 S57 (Pubitemid 41832065)
14. S. Deresinski 2007 Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence Clin Infect Dis 44 1543 1548 (Pubitemid 46871499)
15. M.H. Kollef J. Rello S.K. Cammarata R.V. Croos-Dabrera R.G. Wunderink 2004 Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin Intensive Care Med 30 388 394 (Pubitemid 38375611)
16. M. Wilcox D. Nathwani M. Dryden 2004 Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections J Antimicrob Chemother 53 335 344 (Pubitemid 38239971)
17. J.A. Cepeda T. Whitehouse B. Cooper J. Hails K. Jones F. Kwaku L. Taylor S. Hayman S. Shaw C. Kibbler R. Shulman M. Singer A.P. Wilson 2004 Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study J Antimicrob Chemother 53 345 355 (Pubitemid 38239972)
18. E. Rubinstein S. Cammarata T. Oliphant R. Wunderink the Linezolid Nosocomial Pneumonia Study Group 2001 Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients withnosocomial pneumonia: a randomized, double-blind, multicenter study Clin Infect Dis 32 402 412 (Pubitemid 32173626)
19. R.G. Wunderink S.K. Cammarata T.H. Oliphant M.H. Kollef the Linezolid Nosocomial Pneumonia Study Group 2003 Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia Clin Ther 25 980 992 (Pubitemid 36459702)
20. R.G. Wunderink J. Rello S.K. Cammarata R.V. Croos-Dabrera M.H. Kollef 2003 Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 1789 1797 (Pubitemid 37433574)
21. G. French 2001 Linezolid Int J Clin Pract 55 59 63 (Pubitemid 32148154)
22. J.A. Paladino L.D. Gudgel A. Forrest M.S. Niederman 2002 Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia Chest 122 1271 1279 (Pubitemid 35339540)
23. A.G. Vinken J.Z. Li D.A. Balan B.E. Rittenhouse R.J. Willke C. Goodman 2003 Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Am J Ther 10 264 274
24. A. Vinken Z. Li D. Balan B. Rittenhouse R. Willkie D. Nathwani 2001 Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model J Hosp Infect 49 S13 S24
25. G. Zanetti F. Bally G. Greub J. Garbino T. Kinge D. Lew J.A. Romand J. Bille D. Aymon L. Stratchounski L. Krawczyk E. Rubinstein M.D. Schaller R. Chiolero M.P. Glauser A. Cometta the Cefepime Study Group 2003 Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study Antimicrob Agents Chemother 47 3442 3447 (Pubitemid 37345702)
26. Rote Liste® Service GmbH. Rote Liste. Available at: http://www.rote-liste.de . Accessed 27 Feb 2007.
27. Deutsche Krankenhausgesellschaft Tarif der Deutschen Krankenhausgesellschaft für die Abrechnung erbrachter Leistungen und fur die Kostenerstattung vom Artz an das Krankenhaus DKG-NT Band I. W. Kohlhammer Verlag, July 2005.
28. Einheitlicher Bewertungsmaßstab (EBM). Kassenärztliche Bundesvereinigung Berlin, erstellt am 22.03.2007 (V. 7.0).
29. Institut für das Entgeltsystem im Krankenhaus gGmbH. Abschlussbericht. Weiterentwicklung des G-DRG-Systems für das Jahr 2004. Klassifikation, Katalog und Bewertungsrelationen. Band II: Fallpauschalen- Katalog, Klinische Profile, Kostenprofile, 19 December 2003. Available at: http://inek.customer.msim.de/service/download/Projektbericht2003/ Abschlussbericht-G-DRG-V2004-0312191400-BII.pdf . Accessed 1 Feb 2006.
30. Verband der Privaten Krankenversicherunge.V. Die Private Krankenversicherung. Zahlenbericht 2002/2003. Köln.
31. OECD Health Data 2002: a comparative analysis of 30 countries. Organisation for Economic Co-operation and Development (OECD), Paris. Available at: http://www.OECD.org
32. A.F. Shorr G.M. Susla M.H. Kollef 2004 Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Crit Care Med 32 137 143 (Pubitemid 38125575)
33. C.D. Mullins A. Kuznik F.T. Shaya N.A. Obeidat A.R. Levine L.Z. Liu W. Wong 2006 Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus Clin Ther 28 1184 1198 (Pubitemid 44376813)
34. S. Grau F. Alvarez-Lerma A. del Castillo R. Neipp C. Rubio-Terres 2005 Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain J Chemother 17 203 211 (Pubitemid 40732881)
35. N. Jairath J. Weinstein 1994 The Delphi methodology (part one): a useful administrative approach Can J Nurs Adm 7 29 42
36. N. Jairath J. Weinstein 1994 The Delphi methodology (part two): a useful administrative approach Can J Nurs Adm 7 7 20
37. S. Simoens 2006 Using the Delphi technique in economic evaluation: time to revisit the oracle? J Clin Pharm Ther 31 519 522
38. R.B. Akins H. Tolson B.R. Cole 2005 Stability of response characteristics of a Delphi panel: application of bootstrap data expansion BMC Med Res Methodol 5 37 (Pubitemid 41831543)
39. J. Beyersmann P. Gastmeier H. Grundmann S. Bärwolff C. Geffers M. Behnke H. Rüden M. Schumacher 2006 Use of multistate models to assess prolongation of intensive care unit stay due to nosocomial infection Infect Control Hosp Epidemiol 27 493 499 (Pubitemid 43835532)
40. E.S. Dietrich M. Demmler G. Schulgen K. Fekec O. Mast K. Pelz F.D. Daschner 2002 Nosocomial pneumonia: a cost-of-illness analysis Infection 30 61 67 (Pubitemid 34293368)